Santhera Pharmaceuticals Holding AG Investor Conference Call - Looking Ahead to 2022 Transcript
Good afternoon and good morning, everyone. Thank you for joining today's webcast. Let me start with first introducing our team that's on the call today. Joining me today is Laura Pfeifer-Rossi. She's a partner and equity research analyst from Octavian, a specialized Swiss equity research, brokerage and corporate finance advisory company. She'll be our moderator today for a part of this session.
And from my team here at Santhera, we have Andrew Smith, our CFO; as well as Shabir Hasham, who's our global program lead for vamorolone and he's joining us from his home in London. As an eventful year comes to an end, we want to give you a snapshot of what -- where Santhera stands today and discuss our strategies, plans and goals going forward into 2022 and beyond.
But first to start, I'd like to remind you of where Santhera stood in the late summer of 2020 last year. Our Phase III trial, called SIDEROS had failed and the lead platform for Duchenne muscular dystrophy was discontinued. We had no material pipeline but only a sublicense option
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |